Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Biochem Pharmacol
2021 Nov 01;193:114782. doi: 10.1016/j.bcp.2021.114782.
Show Gene links
Show Anatomy links
Discovery and functional characterization of N-(thiazol-2-yl)-benzamide analogs as the first class of selective antagonists of the Zinc-Activated Channel (ZAC).
Madjroh N
,
Mellou E
,
Davies PA
,
Söderhielm PC
,
Jensen AA
.
???displayArticle.abstract???
The Zinc-Activated Channel (ZAC) is an atypical member of the Cys-loop receptor (CLR) superfamily of pentameric ligand-gated ion channels, with its very different endogenous agonists and signalling properties. In this study, a compound library screening at ZAC resulted in the identification of 2-(5-bromo-2-chlorobenzamido)-4-methylthiazole-5-methyl ester (1) as a novel ZAC antagonist. The structural determinants for ZAC activity in 1 were investigated by functional characterization of 61 analogs at ZAC expressed in Xenopus oocytes by two-electrode voltage clamp electrophysiology, and couple of analogs exerting more potent ZAC inhibition than 1 were identified (IC50 values: 1-3 μM). 1 and N-(4-(tert-butyl)thiazol-2-yl)-3-fluorobenzamide (5a, TTFB) were next applied in studies of the functional properties and the mode of action of this novel class of ZAC antagonists. TTFB was a roughly equipotent antagonist of Zn+- and H+-evoked ZAC signaling and of spontaneous ZAC activity, and the slow on-set of its channel block suggested that its ZAC inhibition is state-dependent. TTFB was found to be a selective ZAC antagonist, exhibiting no significant agonist, antagonist or modulatory activity at 5-HT3A, α3β4 nicotinic acetylcholine, α1β2γ2S GABAA or α1 glycine receptors at 30 μM. 1 displayed largely non-competitive antagonism of Zn2+-induced ZAC signalling, and TTFB was demonstrated to target the transmembrane and/or intracellular domains of the receptor, which collectively suggests that the N-(thiazol-2-yl)-benzamide analog acts a negative allosteric modulator of ZAC. We propose that this first class of selective ZAC antagonists could constitute useful pharmacological tools in future explorations of the presently poorly elucidated physiological functions governed by this CLR.
Abbasi,
Synthesis, Antioxidant and In-Silico Studies of Potent Urease Inhibitors: N-(4-{[(4-Methoxyphenethyl)-(substituted)amino]sulfonyl}phenyl)acetamides.
2019, Pubmed
Abbasi,
Synthesis, Antioxidant and In-Silico Studies of Potent Urease Inhibitors: N-(4-{[(4-Methoxyphenethyl)-(substituted)amino]sulfonyl}phenyl)acetamides.
2019,
Pubmed
Alexander,
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels.
2019,
Pubmed
Bouzat,
Molecular function of α7 nicotinic receptors as drug targets.
2018,
Pubmed
Chatzidaki,
Allosteric modulation of nicotinic acetylcholine receptors.
2015,
Pubmed
Chua,
GABAA Receptors and the Diversity in their Structure and Pharmacology.
2017,
Pubmed
Chua,
Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism.
2016,
Pubmed
,
Xenbase
Coyle,
Structure of GABARAP in two conformations: implications for GABA(A) receptor localization and tubulin binding.
2002,
Pubmed
Davies,
Allosteric modulation of the 5-HT(3) receptor.
2011,
Pubmed
Davies,
A novel class of ligand-gated ion channel is activated by Zn2+.
2003,
Pubmed
Eiselé,
Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities.
1993,
Pubmed
,
Xenbase
Engin,
An Emerging Circuit Pharmacology of GABAA Receptors.
2018,
Pubmed
Fakhfouri,
5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface.
2019,
Pubmed
Gasiorek,
Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors.
2016,
Pubmed
,
Xenbase
Ghosh,
A chimeric prokaryotic-eukaryotic pentameric ligand gated ion channel reveals interactions between the extracellular and transmembrane domains shape neurosteroid modulation.
2017,
Pubmed
,
Xenbase
Gielen,
The desensitization gate of inhibitory Cys-loop receptors.
2015,
Pubmed
,
Xenbase
Grupe,
Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.
2015,
Pubmed
Halliwell,
The mechanism of action and pharmacological specificity of the anticonvulsant NMDA antagonist MK-801: a voltage clamp study on neuronal cells in culture.
1989,
Pubmed
Hammer,
A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude).
2015,
Pubmed
,
Xenbase
Hansen,
Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors.
2011,
Pubmed
,
Xenbase
Hassaine,
X-ray structure of the mouse serotonin 5-HT3 receptor.
2014,
Pubmed
Hibbs,
Principles of activation and permeation in an anion-selective Cys-loop receptor.
2011,
Pubmed
Hosie,
Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites.
2006,
Pubmed
Houtani,
Cloning and expression of ligand-gated ion-channel receptor L2 in central nervous system.
2005,
Pubmed
Iino,
Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.
2009,
Pubmed
In,
Identification and Characterization of NTB451 as a Potential Inhibitor of Necroptosis.
2018,
Pubmed
Jensen,
Ginkgolide X is a potent antagonist of anionic Cys-loop receptors with a unique selectivity profile at glycine receptors.
2010,
Pubmed
Jensen,
Elucidation of molecular impediments in the α6 subunit for in vitro expression of functional α6β4* nicotinic acetylcholine receptors.
2013,
Pubmed
,
Xenbase
Jensen,
Pharmacological characterization of human excitatory amino acid transporters EAAT1, EAAT2 and EAAT3 in a fluorescence-based membrane potential assay.
2004,
Pubmed
Jensen,
Functional characterisation of the human alpha1 glycine receptor in a fluorescence-based membrane potential assay.
2004,
Pubmed
Kim,
Direct Structural Insights into GABAA Receptor Pharmacology.
2021,
Pubmed
Langlhofer,
The Intracellular Loop of the Glycine Receptor: It's not all about the Size.
2016,
Pubmed
Laverty,
Cryo-EM structure of the human α1β3γ2 GABAA receptor in a lipid bilayer.
2019,
Pubmed
Li,
Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog.
2006,
Pubmed
Limon,
Dipicrylamine Modulates GABAρ1 Receptors through Interactions with Residues in the TM4 and Cys-Loop Domains.
2016,
Pubmed
,
Xenbase
Liu,
Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors.
2008,
Pubmed
Lynch,
Glycine Receptor Drug Discovery.
2017,
Pubmed
Madjroh,
Delineation of the functional properties exhibited by the Zinc-Activated Channel (ZAC) and its high-frequency Thr128Ala variant (rs2257020) in Xenopus oocytes.
2021,
Pubmed
,
Xenbase
Madjroh,
Probing the molecular basis for signal transduction through the Zinc-Activated Channel (ZAC).
2021,
Pubmed
,
Xenbase
Mihic,
Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors.
1997,
Pubmed
,
Xenbase
Morales-Perez,
X-ray structure of the human α4β2 nicotinic receptor.
2016,
Pubmed
Nury,
X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel.
2011,
Pubmed
Paradiso,
The C terminus of the human nicotinic alpha4beta2 receptor forms a binding site required for potentiation by an estrogenic steroid.
2001,
Pubmed
,
Xenbase
Polovinkin,
Conformational transitions of the serotonin 5-HT3 receptor.
2018,
Pubmed
Price,
Characterization of a 5-HT3-ELIC Chimera Revealing the Sites of Action of Modulators.
2018,
Pubmed
,
Xenbase
Sams,
Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.
2011,
Pubmed
Satoh,
Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist.
2009,
Pubmed
Sieghart,
Allosteric modulation of GABAA receptors via multiple drug-binding sites.
2015,
Pubmed
Spirova,
Curare alkaloids from Matis Dart Poison: Comparison with d-tubocurarine in interactions with nicotinic, 5-HT3 serotonin and GABAA receptors.
2019,
Pubmed
,
Xenbase
Taly,
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.
2009,
Pubmed
Trattnig,
Copper and protons directly activate the zinc-activated channel.
2016,
Pubmed
Trattnig,
Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site.
2012,
Pubmed
Uto,
Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.
2009,
Pubmed
Walstab,
5-HT(3) receptors: role in disease and target of drugs.
2010,
Pubmed
Winquist,
Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain.
2005,
Pubmed
Wu,
Small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal.
2008,
Pubmed
Yevenes,
Allosteric modulation of glycine receptors.
2011,
Pubmed
Yoon,
Multiple mechanisms of picrotoxin block of GABA-induced currents in rat hippocampal neurons.
1993,
Pubmed
van Muijlwijk-Koezen,
Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists.
2001,
Pubmed
